Sirtex Medical launches new study on liver cancer

Company News

by Jessica Amir

Cancer treatment developer, Sirtex Medical (ASX:SRX) has launched a new investigator led study on the most common form of primary liver cancer.

The study will test the anit-tumour efficacy of Opdivo after Sirtex’s SIR-Spheres has been used in candidates.

The primary endpoint is safety and the key secondary endpoint is overall survival.

The study is expected to recruit 40 patients.

Shares in Sirtex Medical (ASX:SRX) are trading 0.97 per cent lower to $14.30.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.